A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1 ... in studies up to 52 weeks. Also in combination with metformin and ...

incretin mimetics (GLP-1 analogues) and incretin enhancers (DPP-4 inhibitors) are now available for the treatment of Type 2 diabetes. Initial combination therapy with a DPP-4 inhibitor ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

In January 2020, spending on Ozempic, a Type 2 diabetes-indicated GLP-1, was just $4.6 million ... such as Wegovy and Zepbound. This combination of increased usage and expanded state coverage ...

A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor.

In January 2020, spending on Ozempic, a Type 2 diabetes-indicated GLP-1, was just $4.6 million ... such as Wegovy and Zepbound. This combination of increased usage and expanded state coverage ...

According to Innova Market Insights, one in three consumers say they’re intrigued by new, unique and different flavours, and one in four consumers say they’re attracted to interesting and exotic ...

Despite their remarkable efficacy for many populations, GLP-1s have a relatively low persistence rate over time, due to a combination of ... having taken a GLP-1 already — including 43% of ...